Zacks Research Cuts Earnings Estimates for Bausch Health Cos

Bausch Health Cos Inc. (NYSE:BHC) – Research analysts at Zacks Research cut their Q1 2027 EPS estimates for Bausch Health Cos in a note issued to investors on Friday, July 24th. Zacks Research analyst Team now anticipates that the company will earn $0.80 per share for the quarter, down from their prior forecast of $0.82. The consensus estimate for Bausch Health Cos’ current full-year earnings is $4.05 per share. Zacks Research also issued estimates for Bausch Health Cos’ FY2027 earnings at $3.62 EPS, Q1 2028 earnings at $0.58 EPS and FY2028 earnings at $3.08 EPS.

Bausch Health Cos (NYSE:BHC) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $0.78 EPS for the quarter, missing the consensus estimate of $0.81 by ($0.03). The company had revenue of $2.46 billion during the quarter, compared to analysts’ expectations of $2.37 billion. Bausch Health Cos had a negative return on equity of 2,922.77% and a negative net margin of 11.47%.

Other research analysts have also recently issued research reports about the company. Jefferies Financial Group upgraded Bausch Health Cos to a “hold” rating in a research note on Wednesday, July 22nd. Royal Bank Of Canada reduced their price target on Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating on the stock in a research note on Monday, April 27th. Finally, Weiss Ratings lowered Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 4th. Five investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Bausch Health Cos has an average rating of “Reduce” and a consensus target price of $8.00.

Bausch Health Cos Stock Down 0.1%

BHC stock opened at $4.42 on Monday. Bausch Health Cos has a fifty-two week low of $4.33 and a fifty-two week high of $8.69. The company has a market capitalization of $1.66 billion, a price-to-earnings ratio of -1.37 and a beta of 0.42. The business’s 50 day moving average price is $5.00 and its two-hundred day moving average price is $5.54. The company has a debt-to-equity ratio of 54.68, a quick ratio of 0.97 and a current ratio of 1.32.

Insiders Place Their Bets

In other Bausch Health Cos news, Director Frank D. Lee sold 24,456 shares of the firm’s stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $5.43, for a total transaction of $132,796.08. Following the completion of the transaction, the director owned 49,339 shares of the company’s stock, valued at approximately $267,910.77. This trade represents a 33.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 20.67% of the company’s stock.

Institutional Trading of Bausch Health Cos

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Hillsdale Investment Management Inc. purchased a new position in Bausch Health Cos during the fourth quarter valued at $3,651,000. Banco BTG Pactual S.A. purchased a new stake in shares of Bausch Health Cos in the fourth quarter worth $1,186,000. Private Management Group Inc. grew its stake in shares of Bausch Health Cos by 16.7% in the fourth quarter. Private Management Group Inc. now owns 1,892,895 shares of the company’s stock worth $13,156,000 after acquiring an additional 271,170 shares during the last quarter. Ritholtz Wealth Management increased its holdings in shares of Bausch Health Cos by 178.8% during the first quarter. Ritholtz Wealth Management now owns 222,459 shares of the company’s stock valued at $1,201,000 after acquiring an additional 142,663 shares in the last quarter. Finally, Norges Bank bought a new position in shares of Bausch Health Cos during the fourth quarter valued at $25,592,000. Hedge funds and other institutional investors own 78.65% of the company’s stock.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.